Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
Gaba-F-Tic-Oic-Gaba-K-Tic-Oic-Gaba-F-Tic-Oic-Gaba-K-Tic-KKKKK details |
| Primary information | |
|---|---|
| ID | antitb_1755, |
| Name | US 2012/0197004 |
| N-Terminal modification | FKAB-1Gd3 |
| C-Terminal Modification | Gaba-F-Tic-Oic-Gaba-K-Tic-Oic-Gaba-F-Tic-Oic-Gaba-K-Tic-KKKKK |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Amidation |
| Length | Gaba = Gama aminobutyric acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
| Chirality | Linear |
| Nature | 20 |
| Source | L |
| Origin | Hydrophobic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium ranae |
| In Vitro/ In vivo | Mycobacterium ranae |
| Cell Line | MIC = 3 μM |
| Inhibition Concentration | Both |
| Sequence | 2012 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | 29.7 % hemolysis at 100 μM and 10.5 % at 25 μM |
| Immune Responce | Mice |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | None |
| Year of Publication | Anti-bacterial (Salmonella typhimurium, Staphylococcus aureus, Bacillus subtillis) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1796, |
| Name | 17547385 |
| N-Terminal modification | Peptide-40 |
| C-Terminal Modification | GABA-F-Tic-Oic-GABA-K-Tic-Oic-GABA-F-Tic-Oic-GABA-K-Tic-KKKKK |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Amidation |
| Length | GABA = Gama aminobutyric acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
| Chirality | Linear |
| Nature | 19 |
| Source | L |
| Origin | Amphipathic, Hydrophobic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium ranae |
| In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
| Cell Line | MIC = 3 µM or 8.1 µg/mL |
| Inhibition Concentration | Both |
| Sequence | 2007 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | 29.7 % and 10.5 % hemolytic activity at 100 µM and 25 µM peptide respectively |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | Stimulate innate immune system |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
| Tertiary Structure (Technique) | Not Predicted), |